Clinical trials: Central Retinal Vein Occlusion
Neovascular Age-related Macular Degeneration (nAMD), Diabetic Macular Edema (DME), Retinal Vein Occlusion (RVO)
DATA-INSIGHT is a Project That Looks at Health Data in Germany to Find Out How Many Patients Suffer From Eye Disease. The Project Also Explores New Ways to Collect and Use Publicly Available Healthcare Information.
The main goal of this study is to find out how common certain eye diseases are in Germany and how they have changed over time. The diseases being studied are: nAMD (neovascular age-related macular degeneration): a condition that…
- Trial name
- NCT07308639
- Testing
- anti-VEGF medication
- Where
- Germany
- Volunteers
- 50,000 people
- Sponsor
- Bayer
Macular Edema With Central Retinal Vein Occlusions
NEWTON: Aflibercept Injection for Previously Treated Macular Edema Associated With Central Retinal Vein Occlusions
The purpose of the study is to determine the effect of Intravitreal Aflibercept Injection (IAI) on previously treated Central Retinal Vein Occlusions (CRVOs) with other Anti-VEGF agents.
- Trial name
- NEWTON (NCT01870427)
- Testing
- Aflibercept (2.0 mg)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Northern California Retina Vitreous Associates
Diabetic Macular Edema, Age Related Macular Degeneration
Intravitreal Injections of Ziv-aflibercept for Macular Diseases
Diabetic macular edema (DME), wet-AMD and macular edema secondary to vein occlusions are the leading cause of blindness in developed countries.
- Conditions
- Diabetic Macular Edema, Age Related Macular Degeneration, Branch Retinal Vein Occlusion With Macular Edema, Central Retinal Vein Occlusion With Macular Edema
- Trial name
- NCT02556723
- Testing
- Intravitreal injections of ziv-aflibercept
- Where
- Brazil
- Volunteers
- 60 people
- Sponsor
- Retina Clinic, Sao Paulo, Brazil
Retinal Vein Occlusion
Open Label Study to Assess the Efficacy and Safety of AKB-9778 in Subjects With Macular Edema Due to RVO
Phase 2a open-label study to assess the efficacy and safety of subcutaneous 15mg AKB-9778 administered twice daily for 84 days in subjects with macular edema due to RVO.
- Trial name
- NCT02387788
- Testing
- AKB-9778
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Aerpio Therapeutics
Diabetic Retinopathy, Retinal Vein Occlusion
Soluble Cluster of Differentiation 160 (sCD160) in Sera and Intra-ocular Fluids: Association With Ischaemic Retinopathies
CD160 represents a new angiogenic factor as its specific engagement by an agonist monoclonal antibody directed against human CD160 reduced angiogenesis of endothelial cells with a distinct mechanism from current angiogenic…
- Trial name
- NCT03680794
- Testing
- sampling of ophthalmic liquid
- Where
- France
- Volunteers
- 120 people
- Sponsor
- CHU de Reims
Macular Edema, Retinal Vein Occlusion
A Safety and Efficacy Study of OZURDEX® in Macular Edema Associated With Branch Retinal Vein Occlusion
This study will evaluate the safety and efficacy of OZURDEX® (700 µg dexamethasone implant) in patients with macular edema associated with branch retinal vein occlusion.
- Trial name
- COBALT (NCT01903720)
- Testing
- dexamethasone implant
- Where
- South Korea
- Volunteers
- 71 people
- Sponsor
- Allergan
Retinal Vein Occlusion, Macular Edema
A Long-Term Safety Study of OZURDEX® in Clinical Practice
This study is a multicenter, prospective, observational study to evaluate the long-term safety of OZURDEX® in patients with macular oedema following central retinal vein occlusion (CRVO) or branch retinal vein occlusion (BRVO) or…
- Conditions
- Retinal Vein Occlusion, Macular Edema, Uveitis, Posterior
- Trial name
- NCT01539577
- Testing
- dexamethasone 700 μg intravitreal implant
- Where
- 4 sites in France, Germany and 2 more
- Volunteers
- 875 people
- Sponsor
- Allergan
Central Retinal Vein Occlusion
A Study of a Sustained Release Fluocinolone Implant for Treatment of Central Retinal Vein Occlusion
The purpose of this study is to determine whether a fluocinolone sustained drug delivery implant is effective in the treatment of central retinal vein occlusion that has caused persistent macular edema and decreased visual acuity.
- Trial name
- NCT00952614
- Testing
- fluocinolone acetonide (Retisert Implant, Bausch and Lomb)
- Where
- United States
- Volunteers
- 29 people
- Sponsor
- Glenn Jaffe
Retinal Vein Occlusion, Macular Edema
Post Market Surveillance of OZURDEX® for Branch Retinal Vein Occlusion (BRVO) and Central Retinal Vein Occlusion (CRVO)
This multicenter observational study will assess the efficacy and tolerability of OZURDEX® in clinical practice, and will assess the time at which patients are considered for retreatment.
- Trial name
- NCT01568021
- Testing
- No Intervention
- Where
- 3 sites in Denmark, Norway and 1 more
- Volunteers
- 100 people
- Sponsor
- Allergan
Glaucoma, Rubeosis Iridis
Intraocular Bevacizumab (Avastin) for Rubeosis Iridis
Bevacizumab (Avastin®, Roche, Rio de Janeiro, Brazil) is an anti-VEGF recombinant humanized monoclonal IgG1 antibody used to treat colorectal cancers.
- Trial name
- NCT00557232
- Testing
- bevacizumab
- Volunteers
- 25 people, healthy volunteers welcome
- Sponsor
- Instituto de Olhos de Goiania
Retinal Vein Occlusion
Efficacy and Safety of Ranibizumab in Japanese Patients With Retinal Vein Occlusion
The purpose of this study is to provide efficacy and safety data of 3 consecutive monthly intravitreal injections with 0.5 mg ranibizumab in Japanese patients with visual impairment due to macular edema secondary to retinal vein…
- Trial name
- RVO in Japan (NCT01377597)
- Testing
- ranibizumab
- Where
- 8 sites in Japan
- Volunteers
- 47 people
- Sponsor
- Novartis Pharmaceuticals
Retinitis Pigmentosa, Maculopathy, Age Related
High Resolution Retina Imaging
To increase the clinical experience of using the rtx1 camera in various retinal disorders and to follow the evolution of structural alterations during retinal diseases using adaptive optics imaging with the rtx1 camera
- Conditions
- Retinitis Pigmentosa, Maculopathy, Age Related, Macular Dystrophy, Macular Edema
- Trial name
- IHR (NCT04128150)
- Where
- 3 sites in France
- Volunteers
- 1,000 people
- Sponsor
- Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts
Age Related Macular Degeneration, Diabetic Macular Edema
30g vs 33g Needle for Intravitreal Injections
We are comparing the patient experience between the standard 30 g needle to the smaller 33 g needle for intravitreal injections of ranabizumab or aflibercept for age related macular degeneration, diabetic macular edema, or retina…
- Conditions
- Age Related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
- Trial name
- NCT03038048
- Testing
- Varying needle size with intravitreal ranibizumab or aflibercept
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Wills Eye
Retinal Disease, Retinal Detachment
High Resolution Optical Coherence Tomography
Comparison of high-resolution optical coherence tomography (High-Res-OCT) to conventional imaging modalities for the diagnosis of eye diseases
- Conditions
- Retinal Disease, Retinal Detachment, Retinal Vein Occlusion, Retinal Dystrophy
- Trial name
- NCT05130385
- Testing
- High-resolution optical coherence tomography (High-Res-OCT), Standard spectral domain OCT (SD-OCT)
- Where
- Switzerland
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Insel Gruppe AG, University Hospital Bern
Branch Retinal Vein Occlusion
Evaluation of the Usefulness of a PRN Regimen Using Ranibizumab for Macular Edema Due to Branch Retinal Vein Occlusion
Monthly intravitreal ranibizumab (IVR) during the first 6 month had great effect for macular edema with branch retinal vein occlusion (BVO) both in visual and anatomical outcome.
- Trial name
- NCT02478515
- Testing
- Ranibizumab
- Where
- Japan
- Volunteers
- 27 people
- Sponsor
- Nagoya City University
Age-Related Macular Degeneration, Diabetic Retinopathy
National Eye Institute Biorepository for Retinal Diseases
Background: To understand diseases of the retina and the eye, information is needed about people with and without such diseases. Researchers want to study these people and follow them over time.
- Conditions
- Age-Related Macular Degeneration, Diabetic Retinopathy, Von Hippel-Lindau Syndrome, Retinal Disease
- Trial name
- NCT01496625
- Where
- United States
- Volunteers
- 650 people, healthy volunteers welcome
- Sponsor
- National Eye Institute (NEI)
Retinal Vein Occlusion, Macular Edema
Safety and Efficacy Study of Ozurdex® Compared to Lucentis® in Patients With Branch Retinal Vein Occlusion
This study will evaluate the safety and efficacy of dexamethasone intravitreal implant (Ozurdex®) compared to ranibizumab (Lucentis®) in patients with branch retinal vein occlusion (BRVO).
- Trial name
- NCT01427751
- Testing
- dexamethasone intravitreal implant, ranibizumab
- Where
- 6 sites in France, Germany and 4 more
- Volunteers
- 307 people
- Sponsor
- Allergan
Wet Macular Degeneration, Age-related Macular Degeneration
Dorzolamide-timolol Drops With Injections to Treat AMD, RVO or DME.
This study seeks to evaluate the effect of topical aqueous suppression on the anatomic and functional response to intravitreal anti-vascular endothelial growth factor (VEGF) injections in non-responders with wet age-related…
- Conditions
- Wet Macular Degeneration, Age-related Macular Degeneration, Diabetic Macular Edema, Retinal Vein Occlusion
- Trial name
- NCT02571972
- Testing
- Dorzolamide-timolol
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- Wills Eye
Macular Edema, Branch Retinal Vein Occlusion
Sheathotomy vs. Intravitreal Triamcinolone for Branch Retinal Vein Occlusion
Branch retinal vein occlusion (BRVO) is a common retinal vascular disease occurring in a significant number of individuals older than 50 years.The most common cause of visual disturbance in BRVO patients is macular edema, which…
- Trial name
- NCT00612261
- Testing
- Arteriovenous Crossing Sheathotomy, Intravitreal Triamcinolone Acetonide Injection
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Yonsei University
Central Retinal Vein Occlusion
Bevacizumab for Central Retinal Vein Occlusion Study
Central retinal vein occlusion is a leading cause of severe visual impairment. Until now, no treatment has been available to improve visual acuity.
- Trial name
- NCT00906685
- Testing
- bevacizumab
- Where
- Sweden
- Volunteers
- 60 people
- Sponsor
- Anders Kvanta